Cough (Respiratory) Pipeline Review, H2 2019 - Analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type -

DUBLIN--()--The "Cough - Pipeline Review, H2 2019" drug pipelines has been added to's offering.

This report provides an overview of the Cough (Respiratory) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Cough (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cough (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Cough and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Unknown stages are 1, 2, 10, 5, 8 and 1 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.

Cough (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Report Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Cough (Respiratory).
  • The pipeline guide reviews pipeline therapeutics for Cough (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Cough (Respiratory) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Cough (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Cough (Respiratory).

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Cough (Respiratory).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Cough (Respiratory) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Featured News & Press Releases

  • Oct 02, 2019: Congress presentation on clinical study of S-600918, a drug candidate for the treatment of Refractory/Unexplained Chronic Cough
  • Aug 26, 2019: BELLUS Health strengthens leadership team with appointment of Dr. Catherine Bonuccelli, MD as Chief Medical Officer
  • Jul 31, 2019: Bellus Health starts recruitment in Phase II chronic cough trial
  • Jul 25, 2019: Evotec SE: P2X3 antagonist demonstrates efficacy against refractory chronic cough in Phase II (POC)
  • Jul 25, 2019: Positive Phase II data for P2X3 antagonist in patients with refractory chronic cough
  • Jul 15, 2019: BELLUS Health convenes KOL meeting to discuss the state of chronic cough treatment
  • Jun 07, 2019: NeRRe Therapeutics announces positive findings from phase 2b study with orvepitant in chronic cough
  • May 21, 2019: BELLUS Health presents Phase 1 data for BLU-5937, its lead product candidate for the treatment of refractory chronic cough, at the American Thoracic Society International Conference
  • May 15, 2019: BELLUS Health to present at three upcoming healthcare investor conferences
  • May 08, 2019: BELLUS Health provides update on its chronic cough drug candidate BLU-5937
  • Apr 04, 2019: BELLUS Health to Present at Two Upcoming Healthcare Investor Conferences
  • Apr 03, 2019: BELLUS Health announces clearance of U.S. IND for BLU-5937 phase 2 study in chronic cough patients
  • Feb 28, 2019: Evotec receives milestone payment for start of second Phase II trial in its multi-target alliance with Bayer
  • Dec 12, 2018: Altasciences Contributes to Positive Top-Line Phase 1 Results for Chronic Cough Drug Candidate
  • Nov 14, 2018: BELLUS Health updates BLU-5937 top-line phase 1 results timeline to November 2018

Companies Mentioned

  • Alitair Pharmaceuticals Inc
  • Antheia Inc
  • Axalbion SA
  • Bayer AG
  • Beijing Tide Pharmaceutical Co Ltd
  • Charleston Laboratories Inc
  • Conrig Pharma ApS
  • Develco Pharma Schweiz AG
  • Evotec SE
  • Grunenthal GmbH
  • Hyundai Pharmaceutical Co Ltd
  • Merck & Co Inc
  • NeRRe Therapeutics Ltd
  • Nocion Therapeutics Inc
  • Orbis Biosciences Inc
  • PhytoHealth Corp
  • Roivant Sciences Ltd
  • Shionogi & Co Ltd
  • SolAeroMed Inc
  • Trevi Therapeutics Inc
  • Tris Pharma Inc

For more information about this drug pipelines report visit

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900